HP Ingredients Showcases 5 New Studies Performed on LJ100

HP Ingredients has announced five new published human clinical trials for its LJ100 Tongkat Ali (

Eurycoma longifolia) ingredient.

Study 1tested the effects of testosterone levels and quality of life in aging men. The randomized, double-blind, placebo-controlled, multi-center study found split 105 male subjects aged 50-70 years with low testosterone into three groups, and gave them 100mg of LJ100, 200mg of LJ100, or a placebo daily for 12 weeks. The findings:

There was a significant increase in the total testosterone levels at week 12 in the 100mg group and starting at week 4 for the 200mg group compared to the placebo group.
No significant between-group differences in free testosterone levels were observed; however, there was a significant within-group increase starting at week 4 in the 100 mg group, and starting at week 2 in the 200 mg group.
The AMS and FSS showed significant reduction in total scores at all time-points within- and between-group in both LJ100 groups.
DHEA levels significantly increased within-group in both LJ100 groups from week 2 onwards.
Cortisol levels significantly decreased in the 200 mg group, while muscle strength significantly increased in both LJ100 groups at week 12.
Conclusion: Supplementation of 200mg of LJ100 increases serum total testosterone, reduces fatigue, and improves the quality of life in ageing men within only 2 weeks.

Study 2tested LJ100 on sexual health in men with androgen deficiency. The 6-month, double-blind, randomized, placebo-controlled trial split 45 men into four groups: control + placebo; control + LJ100; concurrent training + placebo; concurrent training + LJ100. The findings:

Erectile function improved in the LJ100 groups.
Concurrent training + LJ100 group showed the most significant results in improvement in International Index of Erectile Function (IIEF-5), Aging Male Scale (AMS) and total testosterone.
Conclusion: 200mg LJ100 plus concurrent training improved erectile function and increased total testosterone levels in aging men with androgen deficiency.

Study 3tested LJ100 for strength and cardiorespiratory fitness in men with androgen deficiency. The 6-month, randomized, double-blind, placebo-controlled clinical trial was performed on 45 men, who were randomized into four groups—control, LJ100, concurrent training, and concurrent training + LJ100. The findings:

Isokinetic peak torque of the knee extensors increased in the CT (14%) and CT + LJ100 (17%) groups, the isokinetic peak torque of knee flexion increased in the CT + LJ100 group only.
Testosterone levels were correlated with isokinetic peak torque of knee extension and flexion.
Subjects of the CT (27.3%) and CT + LJ100 (36.1%) groups decreased the symptomatology of androgen deficiency.
Conclusion: This study demonstrated the benefits of CT and LJ100 consumption as a non-pharmacological treatment for androgen deficiency.

Study 4tested the effect of LJ100 on reproductive hormones in young men. The double-blind, placebo-controlled, matched-paired study included 32 men, who received 600mg/day LJ100 or placebo for two weeks. The results:

LJ100 supplementation significantly increased Total Testosterone (+15.21% vs -2.78%), Free Testosterone (+34.12% vs +4%), and estradiol levels (+31.1% vs 20.2%) compared to the placebo.
There was no change in luteinizing hormone, follicle-stimulating hormone and sexual hormone-binding globulin, suggesting a lesser role played by Eurycoma longifolia in activating the hypothalamic-pituitary-gonadal axis in the young adults.
The raised testosterone levels may be due to a greater rate of hormone production via the hypothalamic-pituitary-adrenal axis.
The supplementation of Eurycoma longifolia for two weeks demonstrates steroidogenic effects on young men were dose-related as the earlier study with 200mg did not show significant changes.
Conclusion: The raised testosterone following LJ100 supplementations could benefit muscle and strength gain in young adults.

Study 5,from 2020, tested LJ100 for modulating menopause symptoms for women. The 24-week, randomized, double-blind, placebo-controlled study enrolled 119 healthy women aged 41-55 experiencing peri-menopausal or menopausal symptoms, and supplemented with 400mgL. pumila+ 100mg LJ100, or placebo. The results:

At week 12, significant improvements in hot flash symptoms were observed in the active group compared to placebo.
Significant improvements in MRS and MENQOL scores at weeks 12 and 24 were observed in both groups, respectively.
Luteinizing hormone and follicle-stimulating hormone levels were significantly reduced at weeks 12 and 24 in the Nu-femme group, with no significant changes in placebo group.
Serum LDL-C and triglycerides were significantly reduced at week 12 in Nu-femme group; but no changes in placebo group.
Conclusion: 400 mg L. pumila + 100 mg LJ100 may support reduction in hot flashes and improvements in hormone and lipid profile in healthy peri-menopausal and menopausal women.